Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 305 |
Synonyms | |
Therapy Description |
AMG 305 is a bispecific T-cell engager targeting CDH3 and MSLN, which potentially induces antitumor immune activity (Cancer Res (2023) 83 (7_Supplement): ND06). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 305 | AMG305|AMG-305 | MSLN Antibody 12 | AMG 305 is a bispecific T-cell engager targeting CDH3 and MSLN, which potentially induces antitumor immune activity (Cancer Res (2023) 83 (7_Supplement): ND06). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05800964 | Phase I | AMG 305 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |